Nothing alters our long-term expectations, but we have made some valuation changes.
Here's why mall and shopping center REITs should still expect solid growth.
We expect it to drive growth despite new consumption methods and potential regulation.
Renewable energy has policy momentum, but gas generation offers reliability.
Potential vaping regulations have limited impact on our valuations.
We see some midstream opportunities, but much depends on the speed of recovery.
We see risks for managed care but also opportunities to own moatworthy companies at sizable discounts.
It continues to inflict pain on drug manufacturers and distributors.
We think fears of overbuilding in Manhattan are unwarranted.
Sales were soft in the most recent quarter, but we see brighter days ahead.
Equity valuations remain rich but still offer opportunities for income.
Wide-moat BlackRock and T. Rowe may not be the cheapest, but they're the best.
Fewer acres planted will likely result in lower crop input volumes, but we expect profit impacts to be short-lived.
Sector director Damien Conover shares his key takeaways from Johnson & Johnson, Novartis, Glaxo, and Bristol Myers Squibb's reports.
Those miners appear overpriced, but we see value emerging in base metals and coal.
We see some values, although we don’t think any of the companies have moats.
We see risks as well as opportunities.
We don't see the cryptocurrency having much effect at this point.
Plus, five takeaways from this year's Electrical Products Group Conference.
Nearly all the E&P and oil-services stocks we cover trade below what we think they're worth.
We think both companies' competitive advantages are sustainable.
Our long-term industry assumptions have grown more pessimistic.
We favor Enterprise Products Partners, Tallgrass, and Magellan.
At this point, it looks like more a blip than a roadblock.
TripAdvisor would be most affected; Booking and Expedia less so.
We're not changing our outlook for our midstream coverage.
All three companies still trade at 4 stars, however.
We still think branch networks hold value for customer service and cross-selling.
However, we still expect long-term prices well below current rates and consensus.
The proposal is mostly in line with our expectations, and our valuations haven't changed.
We believe the U.S. banking system is much stronger and more stable than it was a decade ago.
UnitedHealth and CVS are trading at compelling discounts to what we think they’re worth.
A combination is compelling but not without complications.
How economic moats help industrial gas producers consistently deliver lucrative returns.
Heavy-side building materials share prices underestimate the impact of improved funding.
We think the acquiring shareholders are getting a better deal.
Of the contract research organizations we cover, Syneos looks most attractively valued.
We think 3D Systems and Stratasys are both fairly valued.
The road to prohibition will be rocky, but the market assumes a worst-case scenario.
Our long-term outlook for lithium carbonate is unchanged.
The unlikely outcome of a disorderly no-deal Brexit is a risk, but opportunities exist.
We've reduced our long-term pricing forecasts.
Our projection for modest growth in the fiscal 2020 defense budget is now on shakier ground.
Concerns about safety and the fate of private vehicle ownership are just two reasons this technology will stay in first gear for now.
There's too much uncertainty to assume a significant hit to prices.
But we think this is already priced into the shares.
We expect EV sales in China and the EU will accelerate, driving above-consensus global adoption rates.
Online retailers will continue to pressure brick-and-mortar outfits, but we believe that sales at high-quality properties will stay positive.
These companies are finally set to deliver free cash flow, and in several cases the market is missing it.
Although we've raised our estimates, the carriers still look fairly valued.